Multivariate analysis of PRS of metabolite biomarkers as a prognostic factor for OS and EFS in combined training and validation sets
| Variable . | OS . | EFS . | ||
|---|---|---|---|---|
| HR (95% CI)* . | P value . | HR (95% CI)* . | P value . | |
| PRS† | 1.80 (1.17-2.77) | .008 | 1.75 (1.15-2.64) | .008 |
| Age‡ | 1.02 (1.00-1.04) | .06 | 1.02 (1.00-1.03) | .13 |
| WBC‡ | 1.007 (1.003-1.010) | .001 | 1.006 (1.002-1.010) | .002 |
| BM blasts, %‡ | 1.008 (0.999-1.017) | .10 | 1.009 (1.000-1.018) | .05 |
| Treatment protocols§ | .25 | .10 | ||
| T2 vs T1 | 0.62 (0.34-1.11) | .11 | 0.54 (0.31-0.96) | .04 |
| T3 vs T1 | 1.03 (0.56-1.89) | .93 | 0.77 (0.42-1.41) | .39 |
| FLT3-ITD|| | 0.78 (0.43-1.44) | .44 | 0.86 (0.48-1.54) | .62 |
| CEBPA¶ | 0.36 (0.17-0.76) | .008 | 0.49 (0.26-0.93) | .03 |
| NPM1|| | 0.87 (0.54-1.38) | .55 | 0.81 (0.52-1.27) | .36 |
| DNMT3A|| | 1.70 (0.94-3.06) | .08 | 1.56 (0.88-2.75) | .13 |
| MLL-PTD# | 0.93 (0.41-2.08) | .86 | 1.42 (0.70-2.87) | .33 |
| 2-HG** | 1.60 (1.00-2.56) | .05 | 1.83 (1.16-2.88) | .009 |
| Variable . | OS . | EFS . | ||
|---|---|---|---|---|
| HR (95% CI)* . | P value . | HR (95% CI)* . | P value . | |
| PRS† | 1.80 (1.17-2.77) | .008 | 1.75 (1.15-2.64) | .008 |
| Age‡ | 1.02 (1.00-1.04) | .06 | 1.02 (1.00-1.03) | .13 |
| WBC‡ | 1.007 (1.003-1.010) | .001 | 1.006 (1.002-1.010) | .002 |
| BM blasts, %‡ | 1.008 (0.999-1.017) | .10 | 1.009 (1.000-1.018) | .05 |
| Treatment protocols§ | .25 | .10 | ||
| T2 vs T1 | 0.62 (0.34-1.11) | .11 | 0.54 (0.31-0.96) | .04 |
| T3 vs T1 | 1.03 (0.56-1.89) | .93 | 0.77 (0.42-1.41) | .39 |
| FLT3-ITD|| | 0.78 (0.43-1.44) | .44 | 0.86 (0.48-1.54) | .62 |
| CEBPA¶ | 0.36 (0.17-0.76) | .008 | 0.49 (0.26-0.93) | .03 |
| NPM1|| | 0.87 (0.54-1.38) | .55 | 0.81 (0.52-1.27) | .36 |
| DNMT3A|| | 1.70 (0.94-3.06) | .08 | 1.56 (0.88-2.75) | .13 |
| MLL-PTD# | 0.93 (0.41-2.08) | .86 | 1.42 (0.70-2.87) | .33 |
| 2-HG** | 1.60 (1.00-2.56) | .05 | 1.83 (1.16-2.88) | .009 |
Hazard ratios (HRs) >1 correspond to an increased risk of death/relapse compared with the lower values of continuous variables or the reference group of categorical variables.
Low vs high.
Age, WBC, and percentage of BM blasts as continuous variables.
T1, DA regimen; T2, homoharringtonine-based treatment; T3, individualized treatment of elderly patients.
Mutant vs wild-type.
Biallelic CEBPA mutants vs monoallelic CEBPA mutants/wild type.
Positive vs negative.
High vs low as we previously reported.14